Italy's AI Leap: 'Bianca' Project to Revolutionize Cancer Diagnostics

TURIN, Italy – February 10, 2026 – A pioneering initiative in Italy is set to redefine the landscape of cancer diagnostics. The European Institute of Oncology (IEO) and Laife Reply, a specialist in healthcare AI, have joined forces to create "Bianca," the nation's first digital biobank where artificial intelligence is woven directly into the fabric of clinical diagnostic practice. This ambitious project aims to transform the traditional, microscope-centric world of pathology into a seamless, end-to-end digital ecosystem, promising a new era of efficiency, accuracy, and personalized oncology.

Launched in late 2024 and now at its 30-month midway point, the Bianca project is moving from concept to reality. It represents a significant step in a broader journey of technological innovation, structurally integrating advanced research into the routine diagnostic processes that millions of patients rely on.

A National Leap in Digital Health

The Bianca project is not just a hospital-level upgrade; it is a cornerstone of Italy's national strategy to foster technological leadership. Its selection under the "Agreements for Innovation" program, promoted by the Italian Ministry of Enterprises and Made in Italy (MIMIT), underscores its strategic importance. This government program is designed to fund and support industrial research projects with significant technological impact, specifically aiming to enhance the competitiveness of Italian industries through digital transformation.

By backing Bianca, the Italian government is investing in a future where AI and big data are central to healthcare. The project's goals align perfectly with the program's mandate: to develop and adopt highly innovative solutions that can create new, high-value services. This support provides not only financial backing but also a powerful endorsement of the project's potential to set new standards, first within Italy and then potentially across Europe. The initiative is a clear signal of the country's ambition to be at the forefront of the AI revolution in medicine.

Beyond the Microscope: Reinventing Pathology

At the heart of the Bianca project is the monumental task of digitizing the IEO's vast archive of histopathological samples. Using state-of-the-art scanners, physical glass slides containing tissue samples are being converted into ultra-high-resolution digital images. This extensive digital library forms the raw material for training sophisticated AI algorithms designed to see what the human eye might miss and to quantify features with unparalleled precision.

This digital transformation goes far beyond simple image storage. Laife Reply is developing and training AI models on different types of cancer, introducing advanced solutions that fundamentally change the pathologist's workflow. One of the most significant innovations is the use of self-annotation mechanisms. These algorithms can automatically identify and label pathological findings on images, drastically reducing the painstaking and time-consuming manual work traditionally required from clinicians. This not only accelerates the training of more accurate AI models but also frees up expert pathologists to focus on the most complex diagnostic challenges.

Furthermore, the project is venturing into the cutting edge of medical AI by exploring multimodal algorithms. These advanced models are capable of combining the visual data from histopathological images with structured clinical data, such as patient histories, genetic information, and treatment outcomes. By analyzing these diverse data streams in unison, the AI can help identify novel biomarkers and predict information currently obtainable only through complex, costly, and invasive tests. This could dramatically reduce diagnostic time, costs, and the overall burden on patients.

"Bianca represents a turning point for oncological pathology,” said Professor Nicola Fusco, Director of the Pathology Division at IEO. “The integration of digitalisation and AI enables a significant improvement in the quality, standardisation and reproducibility of diagnosis—both histopathological and molecular—by optimising the entire workflow, reducing reporting times, rationalising costs and improving the overall efficiency of diagnostic services for our patients. At the same time, the project contributes to the training of a new generation of pathologists with highly specialised skills, capable of combining morphological and molecular expertise with advanced digital tools and AI algorithms, paving the way for a sustainable evolution of oncological diagnostics.”

Building a Scalable Framework for European Healthcare

While the collaboration with IEO provides the perfect incubator, the vision for Bianca extends far beyond the walls of a single institution. Laife Reply and its parent, the Reply Group, are explicitly building a "scalable and industrialisable framework" designed for widespread adoption. This strategy positions the project not as a bespoke research tool, but as a future-proof product for the broader healthcare market.

Global competitors like Paige.AI and PathAI have already demonstrated the power of AI in analyzing pathology slides, but Bianca's emphasis on creating a fully integrated end-to-end ecosystem for routine clinical use in a European context sets it apart. The goal is to offer a complete package that includes sample digitalization, advanced analytics, and the infrastructure to run it all, making it accessible even to smaller hospitals and healthcare organizations that lack the resources to develop such systems independently.

“With Bianca, we are collaborating with IEO to support the evolution of pathology in the oncological field,” said Carlo Malgieri, Partner at Laife Reply. “This is not just about applying artificial intelligence to individual cases, but about building a scalable and industrialisable framework designed to be offered to hospitals and smaller healthcare organisations. The framework integrates sample digitalisation, advanced algorithms and high-performance analytics infrastructures. This approach makes it possible to support clinicians, enable new services for healthcare systems and oncological research, and ensure transparency and explainability—key elements to guarantee that every algorithm-supported decision is trustworthy.”

This commercial strategy is crucial. By making the technology scalable, Reply aims to democratize access to cutting-edge diagnostics, potentially improving standards of care across entire healthcare systems and establishing a strong foothold in the rapidly growing European digital health market.

Navigating the Complexities of AI in Medicine

Deploying a powerful AI system like Bianca into clinical practice involves clearing significant regulatory and ethical hurdles. The project's success will depend as much on navigating this complex landscape as it will on its technological prowess. Under the forthcoming EU AI Act, diagnostic tools like Bianca will almost certainly be classified as "high-risk," subjecting them to a battery of stringent requirements.

These regulations will mandate robust risk management, high-quality data governance to prevent bias, comprehensive technical documentation, and, critically, mechanisms for effective human oversight. The system must be proven to be accurate, secure, and robust. Furthermore, compliance with the EU's Medical Device Regulation (MDR) and the General Data Protection Regulation (GDPR) is non-negotiable, requiring rigorous clinical validation and ironclad protection of sensitive patient data.

The project's architects appear keenly aware of these challenges. The emphasis on "transparency and explainability" is a direct response to the "black box" problem that plagues many AI systems. For a clinician to trust an AI's recommendation in a life-or-death decision, they must have a degree of insight into how that conclusion was reached. Building this trust—with clinicians, regulators, and patients—is the ultimate test. Successfully navigating this intricate web of rules and ethics will be the final, crucial step in allowing Bianca to realize its transformative potential for cancer care in Italy and beyond.